Get the Stockscreener App
11.14
2.39%
0.26
Stoke Therapeutics Inc stock is traded at $11.14, with a volume of 463.03K.
It is up +2.39% in the last 24 hours and up +27.31% over the past month.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
See More
Previous Close:
$10.88
Open:
$11.05
24h Volume:
463.03K
Relative Volume:
0.59
Market Cap:
$520.85M
Revenue:
$8.78M
Net Income/Loss:
$-104.70M
P/E Ratio:
-4.7004
EPS:
-2.37
Net Cash Flow:
$-82.68M
1W Performance:
+16.77%
1M Performance:
+27.31%
6M Performance:
-16.05%
1Y Performance:
-26.76%
1-Day Range:
$11.05
$11.35
1-Week Range:
$9.47
$11.42
52-Week Range:
$5.35
$17.58
Stoke Therapeutics Inc Stock (STOK) Company Profile
Name
Stoke Therapeutics Inc
Sector
Industry
Phone
781-430-8200
Address
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
11.14 | 520.85M | 8.78M | -104.70M | -82.68M | -2.37 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.50 | 113.52B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
493.22 | 52.93B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
300.83 | 39.71B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
585.93 | 35.00B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
255.86 | 26.57B | 3.81B | -644.79M | -669.77M | -6.24 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Mar-26-24 | Upgrade | TD Cowen | Market Perform → Outperform |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Jul-25-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-01-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Apr-26-23 | Resumed | Canaccord Genuity | Buy |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Oct-24-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-31-22 | Initiated | Jefferies | Buy |
| Dec-03-21 | Initiated | BofA Securities | Buy |
| Nov-22-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-18-21 | Initiated | UBS | Neutral |
| May-10-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-15-20 | Resumed | H.C. Wainwright | Buy |
| Dec-11-20 | Reiterated | Needham | Buy |
| Oct-23-20 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Sep-29-20 | Initiated | Needham | Buy |
| Dec-18-19 | Initiated | Wedbush | Outperform |
| Nov-12-19 | Initiated | BTIG Research | Buy |
| Oct-25-19 | Initiated | H.C. Wainwright | Buy |
| Jul-15-19 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Cowen | Outperform |
| Jul-15-19 | Initiated | Credit Suisse | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
View All
Stoke Therapeutics Inc Stock (STOK) Latest News
(STOK) Technical Data - news.stocktradersdaily.com
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Insider Sell: Barry Ticho Sells 8,216 Shares of Stoke Therapeuti - GuruFocus
Insider Sell: Barry Ticho Sells 8,216 Shares of Stoke Therapeutics Inc (STOK) - GuruFocus
Stoke Therapeutics Adopts Key Proposals at Annual Meeting - TipRanks
BNP Paribas Financial Markets Trims Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
ProShare Advisors LLC Acquires Shares of 12,626 Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Contrasting Stoke Therapeutics (NASDAQ:STOK) & Renovaro (NASDAQ:RENB) - Defense World
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference | STOK Stock News - GuruFocus
Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference - Business Wire
D. E. Shaw & Co. Inc. Sells 143,203 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
How to Take Advantage of moves in (STOK) - news.stocktradersdaily.com
Northern Trust Corp Purchases 11,635 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 28% But Its Business Still Trails The Industry - simplywall.st
Chardan Capital Has Strong Forecast for STOK FY2025 Earnings - Defense World
Analysts Issue Forecasts for STOK FY2026 Earnings - Defense World
Research Analysts Issue Forecasts for STOK FY2025 Earnings - Defense World
Wall Street Analysts Think Stoke Therapeutics (STOK) Could Surge 132.4%: Read This Before Placing a Bet - MSN
HC Wainwright Analysts Decrease Earnings Estimates for STOK - Defense World
Q2 EPS Estimates for Stoke Therapeutics Raised by Wedbush - Defense World
Stoke Therapeutics (NASDAQ:STOK) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
Stoke Therapeutics stock target cut to $35 by H.C. Wainwright - Investing.com Canada
Price T Rowe Associates Inc. MD Purchases 2,215 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
STOK: HC Wainwright & Co. Maintains Buy Rating on Stoke Therapeu - GuruFocus
Stoke Therapeutics (STOK) Sees Adjusted Price Target Amid Upcoming Trial | STOK Stock News - GuruFocus
Stoke Therapeutics (STOK) Sees Adjusted Price Target Amid Upcomi - GuruFocus
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - BioSpace
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up After Better-Than-Expected Earnings - Defense World
Stoke Therapeutics Advances with Strong Q1 2025 Results - TipRanks
Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates | STOK Stock News - GuruFocus
Stoke Therapeutics (STOK) Reports Significant Q1 Revenue Growth - GuruFocus
Stoke Therapeutics, Inc. (STOK) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Stoke Therapeutics Provides Business Updates - citybiz
Stoke Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Stoke Therapeutics Inc (STOK) Reports Q1 2025 Earnings: EPS of $ - GuruFocus
Stoke Therapeutics Q1 Operating Income USD 111.24 Million - marketscreener.com
Stoke Therapeutics Inc (STOK) Reports Q1 2025 Earnings: EPS of $1.90 and Revenue of $158.6 Million, Surpassing Estimates - GuruFocus
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Purchased by Dimensional Fund Advisors LP - Defense World
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Gaining Ground: Stoke Therapeutics Inc (STOK) Closes Lower at 8.87, Down -1.44 - DWinneX
Wells Fargo & Company MN Has $185,000 Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Invesco Ltd. Takes Position in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
JPMorgan Chase & Co. Boosts Stock Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Form DEF 14AOther definitive proxy statements - ADVFN
Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Monday - Defense World
Technical analysis of Stoke Therapeutics Inc (STOK) stock chart patterns - uspostnews.com
Biogen tops estimates on rare disease strength, cuts full-year guidance - The Pharma Letter
Biogen lowers annual earnings outlook, surpasses Q1 estimates By Investing.com - Investing.com Canada
Legal & General Group Plc Decreases Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK) - Defense World
Biogen (BIIB) Lowers Profit Outlook After Deal for Epilepsy Drug - Bloomberg
Market Momentum Report: Stoke Therapeutics Inc (STOK)’s Negative Close at 9.47 - DWinneX
Stoke Therapeutics Inc Stock (STOK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):